title: Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acids.
abstract: The aim of this study was to conduct a systematic review on the photoinactivators used in hemotherapy, with action on viral genomes. The SciELO, Science Direct, PubMed and Lilacs databases were searched for articles. The inclusion criterion was that these should be articles on inactivators with action on genetic material that had been published between 2000 and 2010. The key words used in identifying such articles were "hemovigilance", "viral inactivation", "photodynamics", "chemoprevention" and "transfusion safety". Twenty-four articles on viral photoinactivation were found with the main photoinactivators covered being: methylene blue, amotosalen HCl, S-303 frangible anchor linker effector (FRALE), riboflavin and inactin. The results showed that methylene blue has currently been studied least, because it diminishes coagulation factors and fibrinogen. Riboflavin has been studied most because it is a photoinactivator of endogenous origin and has few collateral effects. Amotosalen HCl is effective for platelets and is also used on plasma, but may cause changes both to plasma and to platelets, although these are not significant for hemostasis. S-303 FRALE may lead to neoantigens in erythrocytes and is less indicated for red-cell treatment; in such cases, PEN 110 is recommended. Thus, none of the methods for pathogen reduction is effective for all classes of agents and for all blood components, but despite the high cost, these photoinactivators may diminish the risk of blood-transmitted diseases.
authors.affiliation: Empresa Brasileira de Hemoderivados e Biotecnologia, HEMOBRAS, Recife, PE, Brazil.
authors.forename: Patricia Marial
authors.initials: PM
authors.lastname: Sobral
authors.forename: Artur Emilio de Lima
authors.initials: AE
authors.lastname: Barros
authors.forename: Ayla Maritcha Alves Silva
authors.initials: AM
authors.lastname: Gomes
authors.forename: Cristine Vieira
authors.initials: CV
authors.lastname: do Bonfim